Global Primary Immunodeficiency Therapeutics Market
Sizing, Segmentation, & Growth Forecast (2025-2030)
Last updated: August 2026
Report Scope: The downloadable datasheet contains market sizes in USD for the period 2025-30.
Market Breakdown: Sizes and growth rates are broken down by geography and market segment (see below for details).
1. Summary
The Global Primary Immunodeficiency Therapeutics Market was valued at $9.4 bn. in 2025. During the forecast period 2025-2030, it is expected to grow at 6.8% CAGR, to an estimated market size of $13.1 bn. in 2030. A detailed breakdown by segment and geography is provided in the downloadable datasheet.
2. Market Definition
The Global Primary Immunodeficiency (PID) Therapeutics Market includes the research, development, and commercialization of pharmaceutical treatments for over 450 rare, congenital disorders where the immune system is missing or dysfunctional. The scope encompasses immunoglobulin replacement therapies (IVIG and SCIG), gene therapies, hematopoietic stem cell transplants, and supportive treatments like antibiotics and targeted biologics, while excluding diagnostics-only services.
3. Trends & Demand Drivers
Several key trends are expected to significantly impact the Primary Immunodeficiency Therapeutics Market in the period 2025-30:
- The market is experiencing a paradigm shift from symptomatic management to curative gene therapies using lentiviral vectors and CRISPR-Cas9 technology.
- Expansion of newborn screening programs globally is significantly increasing early diagnosis rates for conditions like Severe Combined Immunodeficiency (SCID).
- There is a growing patient preference for subcutaneous immunoglobulin (SCIG) over intravenous delivery to facilitate home-based self-administration.
- Advancements in Next-Generation Sequencing (NGS) are enabling more precise molecular diagnosis and the development of personalized treatment plans.
- Regulatory incentives, such as orphan drug designations and accelerated approval pathways, are driving increased R&D investment from major biopharmaceutical firms.
- The integration of Artificial Intelligence (AI) in analyzing electronic health records is improving the identification of undiagnosed PID patients.
- Rising adoption of value-based care models is influencing pricing strategies and reimbursement for high-cost curative treatments.
4. Market Breakdown
The downloadable datasheet breaks market sizes and growth rates (CAGRs) down into the following geographies and segments:
Geographies
- North America
- Europe
- Asia-Pacific
- Rest of World
Segments
- Immunoglobulin Replacement Therapy
- Gene Therapy
- Stem Cell & Bone Marrow Transplant
- Antibiotics & Other Biologics